Chimerix (NASDAQ:CMRX) Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Chimerix (NASDAQ:CMRX) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Several other analysts have also issued reports on the stock. ValuEngine lowered shares of WideOpenWest from a hold rating to a sell rating in a report on Friday, June 28th. Cowen reiterated a hold rating on shares of PDL BioPharma in a research note on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $4.75.

Shares of CMRX opened at $3.69 on Wednesday. Chimerix has a 12-month low of $1.74 and a 12-month high of $4.83. The firm has a 50-day moving average of $3.62.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.00 million. Chimerix had a negative net margin of 757.77% and a negative return on equity of 36.85%. As a group, equities analysts predict that Chimerix will post -1.02 earnings per share for the current year.

In other Chimerix news, Director Martha J. Demski purchased 18,000 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were bought at an average cost of $3.60 per share, for a total transaction of $64,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Fred A. Middleton purchased 30,000 shares of the business’s stock in a transaction on Friday, May 10th. The shares were acquired at an average price of $2.92 per share, for a total transaction of $87,600.00. Following the completion of the purchase, the director now directly owns 97,523 shares of the company’s stock, valued at $284,767.16. The disclosure for this purchase can be found here. Insiders have acquired 78,000 shares of company stock worth $256,800 over the last quarter. Insiders own 12.50% of the company’s stock.

A number of large investors have recently modified their holdings of CMRX. Opaleye Management Inc. increased its stake in Chimerix by 70.5% during the fourth quarter. Opaleye Management Inc. now owns 2,020,000 shares of the biopharmaceutical company’s stock worth $5,191,000 after purchasing an additional 835,000 shares during the period. RBF Capital LLC acquired a new position in shares of Chimerix during the fourth quarter worth about $1,220,000. 683 Capital Management LLC acquired a new position in shares of Chimerix during the fourth quarter worth about $771,000. Acadian Asset Management LLC grew its position in shares of Chimerix by 106.1% during the first quarter. Acadian Asset Management LLC now owns 482,557 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 248,401 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Chimerix by 21.6% during the fourth quarter. Geode Capital Management LLC now owns 645,273 shares of the biopharmaceutical company’s stock worth $1,658,000 after buying an additional 114,702 shares in the last quarter. Institutional investors own 69.71% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Featured Article: What is a stock buyback?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.